The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).
Christof Vulsteke
No relevant relationships to disclose
Diether Lambrechts
No relevant relationships to disclose
Anne-Sophie Dieudonné
No relevant relationships to disclose
Sigrid Hatse
No relevant relationships to disclose
Barbara Brouwers
No relevant relationships to disclose
Thomas Van Brussel
No relevant relationships to disclose
Patrick Neven
No relevant relationships to disclose
Ann Belmans
No relevant relationships to disclose
Patrick Schoffski
No relevant relationships to disclose
Robert Paridaens
No relevant relationships to disclose
Hans Wildiers
Research Funding - Amgen